Fujirebio Diagnostics, Inc. Sustainability Profile
Fujirebio Diagnostics, Inc., a leading player in the diagnostics industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1950, the company has established itself as a pioneer in the development of innovative diagnostic solutions, particularly in the fields of oncology and infectious diseases. Fujirebio is renowned for its advanced biomarker technologies and high-quality assays, which are integral to disease detection and monitoring. Their flagship products, including the Lumipulse® platform, stand out for their precision and reliability, catering to the evolving needs of healthcare professionals. With a strong market position, Fujirebio has achieved significant milestones, including numerous regulatory approvals and partnerships that enhance its global reach. The company continues to drive advancements in diagnostics, contributing to improved patient outcomes worldwide.
DitchCarbon Score
How does Fujirebio Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fujirebio Diagnostics, Inc.'s score of 54 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fujirebio Diagnostics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of H.U. Group Holdings, Inc., any climate commitments or emissions data may be influenced by the parent company's initiatives. Fujirebio Diagnostics has not publicly disclosed any reduction targets or significant achievements in emissions reduction. The company is part of a broader corporate family that may have its own sustainability goals, but specific details regarding Fujirebio's individual commitments or performance are not provided. As part of its corporate structure, emissions data and climate initiatives may be cascaded from H.U. Group Holdings, Inc., which could include targets set under the Science Based Targets initiative (SBTi) and other climate-related frameworks. However, without specific emissions figures or reduction targets from Fujirebio Diagnostics, it is challenging to assess their direct impact on carbon emissions or their commitment to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 10,712,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 22,822,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 354,925,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Fujirebio Diagnostics, Inc.'s Industry?
How Carbon Intensive is Fujirebio Diagnostics, Inc.'s Location?
Fujirebio Diagnostics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fujirebio Diagnostics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
